VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
MBS303
Phase 2
Small molecule
B
Beijing Mabworks Biotech Co., Ltd.
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
B-Cell NHL
Recruiting
Preclinical
Phase 1
Phase 2
Phase 3
Approved
B-Cell NHL
Phase 2
Recruiting
Clinical
Trials by Indication
[1]
B-cell NHL
1 trial
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Recruiting
·
B
Beijing Mabworks Biotech Co., Ltd.
·
Phase 1/2
·
NCT05806099
·
132 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for MBS303. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
MBS303 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for MBS303. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Beijing Mabworks Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
B
Beijing Mabworks Biotech Co., Ltd.
Related News